The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

New formulation supports adaptable care delivery in oncology settings with limited capacity or remote patient populations ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

H.C. Wainwright’s Mitchell Kapoor maintained Halozyme Therapeutics Inc. (NASDAQ:HALO) at a $72 price target and a Buy rating ...

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. This ...

Bristol Myers on Wednesday said the European Commission approved the subcutaneous formulation of Opdivo for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following ...

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the ...

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.